Department of Orthopedics, The First Hospital of Lanzhou University, Lanzhou 730000, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Biosci Rep. 2018 Nov 20;38(6). doi: 10.1042/BSR20181384. Print 2018 Dec 21.
Human osteosarcoma is the most frequent primary malignant of bone, and often occurs in adolescents. However, molecular mechanism of this disease remains unclear. In the present study, we found that the level of Rhotekin 2 (RTKN2) was up-regulated in osteosarcoma tissues and cell lines. In addition, silencing of RTKN2 of human osteosarcoma cell lines U2OS, inhibited proliferation, and induced G phase cell cycle arrest via reducing the level of the cyclin-dependent kinase 2 (CDK2). Furthermore, RTKN2 knockdown in the U2OS cells induced apoptosis by increasing the level of Bax and decreasing the level of Bcl2. These results suggested that RTKN2 is involved in the progression of human osteosarcoma, and may be a potential therapeutic target.
人骨肉瘤是最常见的原发性恶性骨肿瘤，常发生于青少年。然而，这种疾病的分子机制尚不清楚。在本研究中，我们发现 Rhotekin 2（RTKN2）的水平在骨肉瘤组织和细胞系中上调。此外，沉默人骨肉瘤细胞系 U2OS 中的 RTKN2，通过降低周期蛋白依赖性激酶 2（CDK2）的水平，抑制增殖，并诱导 G 期细胞周期停滞。此外，U2OS 细胞中 RTKN2 的敲低通过增加 Bax 的水平和降低 Bcl2 的水平诱导细胞凋亡。这些结果表明 RTKN2 参与了人骨肉瘤的进展，可能是一个潜在的治疗靶点。
